AGTC to Present at Upcoming Investor Conferences

Rhea-AI Summary

Applied Genetic Technologies Corporation (Nasdaq: AGTC), a leading biotechnology firm focused on gene therapies for rare diseases, announced its participation in two significant virtual investor conferences. The H.C. Wainwright Global Life Sciences Conference will feature a fireside chat with CEO Sue Washer on March 9, 2021, while the 33rd Annual ROTH Conference will include both Washer and Chief Scientific Officer Mark Shearman on March 15, 2021. Audio webcasts will be available on demand at AGTC's website following each event.

GAINESVILLE, Fla. and CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that management will be participating in the following virtual investor conferences:

• H.C. Wainwright Global Life Sciences Conference ‎(March 9-10, 2021)
  A fireside chat with Sue Washer, President & Chief Executive Officer, will be available to view on-demand beginning Tuesday, March 9, 2021 at 7:00 a.m. ET through the entirety of the conference.

• 33rd Annual ROTH Conference (March 15-17, 2021)
  Ms. Washer and Mark Shearman, Chief Scientific Officer, will participate in a fireside chat at 1:00 p.m. ET on Monday, March 15, 2021.
  

Audio webcasts of the presentation at the H.C. Wainwright and ROTH conferences can be accessed by visiting http://ir.agtc.com/events-and-presentations. A replay will be available on the Company's website following the events.

About AGTC
AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. AGTC’s most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 and ACHM CNGA3). Its preclinical programs build on the Company’s industry-leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.

IR/PR CONTACTS: 
David Carey (IR) or Glenn Silver (PR)
Lazar FINN Partners
T: (212) 867-1768 or (646) 871-8485
david.carey@finnpartners.com or glenn.silver@finnpartners.com

Corporate Contacts:
Bill Sullivan
Chief Financial Officer
Applied Genetic Technologies Corporation
T: (617) 843-5728  
bsullivan@agtc.com

Stephen Potter
Chief Business Officer
Applied Genetic Technologies Corporation
T: (617) 413-2754
spotter@agtc.com 

 

FAQ

What conferences is AGTC participating in March 2021?

AGTC will participate in the H.C. Wainwright Global Life Sciences Conference on March 9-10 and the 33rd Annual ROTH Conference on March 15-17, 2021.

Who will represent AGTC at the H.C. Wainwright Conference?

CEO Sue Washer will represent AGTC in a fireside chat available on demand starting March 9, 2021.

When will AGTC's fireside chat at the ROTH Conference take place?

AGTC's fireside chat at the ROTH Conference is scheduled for 1:00 p.m. ET on March 15, 2021.

Where can I access AGTC's conference presentations?

You can access AGTC's conference presentations via audio webcasts on their official website after the events.

What is AGTC's focus in biotechnology?

AGTC focuses on developing gene therapies for rare and debilitating diseases, especially in the ophthalmic and central nervous system areas.